The earnings call highlighted solid revenue growth and positive net income, with successful enrollment in clinical trials and increased marketing reach. However, the decrease in new prescriptions and enrollments, along with challenges in China, present areas of concern.

Company Guidance

During the second quarter of 2025, Puma Biotechnology reported total revenue of $52.3 million, with net product revenue from NERLYNX sales amounting to $49.2 million, marking an increase from $43.1 million in Q1 2025 and $44.4 million in Q2 2024. The company also recorded royalty revenue of $3.2 million, an increase from $2.9 million in Q1 2025. NERLYNX ex-factory bottle sales totaled 2,608, showing a 12% increase quarter-over-quarter and a 4% increase year-over-year, despite a 72-bottle inventory decrease. New prescriptions fell by approximately 3% compared to Q1 2025, whereas total prescriptions increased by roughly 3%. Puma's net income for the quarter stood at $5.9 million or $0.12 per share on a GAAP basis and $7.5 million or $0.15 per share on a non-GAAP basis, with a gross-to-net adjustment remaining at 20.8%. The company anticipates a full-year 2025 net NERLYNX product revenue between $192 million and $198 million, maintaining a focus on expanding NERLYNX utilization and engaging with healthcare providers.

Revenue Growth

Total revenue for Q2 2025 was $52.3 million, with net product revenue from NERLYNX sales at $49.2 million, up from $43.1 million in Q1 2025 and $44.4 million in Q2 2024.

Increased NERLYNX Sales

NERLYNX ex-factory bottle sales were 2,608 in Q2 2025, a 12% increase quarter-over-quarter and a 4% increase year-over-year.

Positive Net Income

Reported GAAP net income of $5.9 million or $0.12 per share in Q2 2025, up from $3 million or $0.06 per share in Q1 2025.

Enrollment in Clinical Trials Ahead of Expectations

The ALISCA-Breast trial is enrolling faster than anticipated with 62 patients enrolled and 10 additional in screening.

Increased Marketing Reach

Year-to-date, reached 99.7% of oncologists through nonpersonal promotion, with new strategies to engage physicians.

Puma Biotechnology (PBYI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PBYI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.04 / -	0.41	―	―	―
Aug 07, 2025	2025 (Q2)	0.09 / 0.12	-0.09	233.33% (+0.21)
May 08, 2025	2025 (Q1)	-0.02 / 0.06	-0.1	160.00% (+0.16)
Feb 27, 2025	2024 (Q4)	0.09 / 0.39	0.26	50.00% (+0.13)
Nov 07, 2024	2024 (Q3)	0.33 / 0.41	0.12	241.67% (+0.29)
Aug 01, 2024	2024 (Q2)	-0.13 / -0.09	0.05	-280.00% (-0.14)
May 02, 2024	2024 (Q1)	-0.22 / -0.10	0.03	-433.33% (-0.13)
Feb 29, 2024	2023 (Q4)	0.30 / 0.26	-0.12	316.67% (+0.38)
Nov 02, 2023	2023 (Q3)	0.08 / 0.12	-0.01	1300.00% (+0.13)
Aug 03, 2023	2023 (Q2)	0.01 / 0.05	0.21	-76.19% (-0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PBYI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$3.29	$3.69	+12.16%
May 08, 2025	$3.07	$2.91	-5.21%
Feb 27, 2025	$2.99	$3.58	+19.73%
Nov 07, 2024	$3.03	$2.88	-4.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Puma Biotechnology (PBYI) report earnings?

Puma Biotechnology (PBYI) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Puma Biotechnology (PBYI) earnings time?

Puma Biotechnology (PBYI) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PBYI EPS forecast?

PBYI EPS forecast for the fiscal quarter 2025 (Q3) is 0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing